Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Acker

Showing results (271-280 of 287) with videos related to

Pageof 29
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|December 16, 2014
Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitationIrving L Kron, Judy Hung, Jessica R Overbey, et al.
JTCVS Structural and Endovascular|May 14, 2026
Association of tricuspid regurgitation with clinical events and quality of life after surgery for severe ischemic mitral regurgitationRaymond J Strobel, Benjamin P Kramer, Jessica R Overbey, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring systemRobert O Hughes, John K Walker, Jerry W Cubbage, et al.
Journal of the American College of Cardiology|July 26, 2014
Management practices and major infections after cardiac surgeryAnnetine C Gelijns, Alan J Moskowitz, Michael A Acker, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 9, 2022
Intimal hyperplasia, saphenous vein graft disease, and clinical outcomes: Insights from the CTSN VEST randomized trialDaniel J Goldstein, Helena L Chang, Michael J Mack, et al.
Journal of Medicinal Chemistry|March 4, 2010
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5)Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, et al.
The New England Journal of Medicine|November 20, 2013
Mitral-valve repair versus replacement for severe ischemic mitral regurgitationMichael A Acker, Michael K Parides, Louis P Perrault, et al.
The New England Journal of Medicine|November 19, 2014
Surgical treatment of moderate ischemic mitral regurgitationPeter K Smith, John D Puskas, Deborah D Ascheim, et al.
JAMA|March 27, 2019
Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical TrialTerrence M Yau, Francis D Pagani, Donna M Mancini, et al.
The New England Journal of Medicine|November 10, 2015
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral RegurgitationDaniel Goldstein, Alan J Moskowitz, Annetine C Gelijns, et al.
Pageof 29

Showing results (271-280 of 287) with videos related to

Sort By:
Pageof 29
The Journal of Thoracic and Cardiovascular Surgery|December 16, 2014
Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitationIrving L Kron, Judy Hung, Jessica R Overbey, et al.
JTCVS Structural and Endovascular|May 14, 2026
Association of tricuspid regurgitation with clinical events and quality of life after surgery for severe ischemic mitral regurgitationRaymond J Strobel, Benjamin P Kramer, Jessica R Overbey, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring systemRobert O Hughes, John K Walker, Jerry W Cubbage, et al.
Journal of the American College of Cardiology|July 26, 2014
Management practices and major infections after cardiac surgeryAnnetine C Gelijns, Alan J Moskowitz, Michael A Acker, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 9, 2022
Intimal hyperplasia, saphenous vein graft disease, and clinical outcomes: Insights from the CTSN VEST randomized trialDaniel J Goldstein, Helena L Chang, Michael J Mack, et al.
Journal of Medicinal Chemistry|March 4, 2010
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5)Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, et al.
The New England Journal of Medicine|November 20, 2013
Mitral-valve repair versus replacement for severe ischemic mitral regurgitationMichael A Acker, Michael K Parides, Louis P Perrault, et al.
The New England Journal of Medicine|November 19, 2014
Surgical treatment of moderate ischemic mitral regurgitationPeter K Smith, John D Puskas, Deborah D Ascheim, et al.
JAMA|March 27, 2019
Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical TrialTerrence M Yau, Francis D Pagani, Donna M Mancini, et al.
The New England Journal of Medicine|November 10, 2015
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral RegurgitationDaniel Goldstein, Alan J Moskowitz, Annetine C Gelijns, et al.
Pageof 29